AXL and melanoma: Therapeutically, targeting pathways that sustain this reprogramming, particularly the AXL/YAP, IL-6/gp130, and COX-2–PGE2 axes, represent a promising approach to reduce melanoma adaptability and improve long-term treatment outcomes.